
From left to right: Paul Markell, Chief Operating Officer, Spartan Bioscience; Mark D. Kershey, VP Corporate Development, Spartan Bioscience; Paul Lem, M.D., CEO & Founder, Spartan Bioscience; Dr. Jack Kitts, President and CEO, The Ottawa Hospital.
“As a one-hour point-of-care test, the Spartan RX CYP2C19 has the potential to significantly reduce major cardiac events in heart attack patients. ”
Dr. Derek So, M.D.
Staff cardiologist
University of Ottawa Heart Institute
Albuquerque, New Mexico / August 12-13, 2008 / Booth #304
http://chppm-www.apgea.army.mil/fhp/
Grapevine, Texas / August 12-13, 2008 / Booth #215
http://www.amp.org/2008/index.htm/